2025
Advancing the Evaluation and Management of CDH1-Associated Gastric Cancer.
Lerner B, Gupta S, Burke C, Kupfer S, Katona B, Grady W, Samadder J, Yurgelun M, Kelly K, Moreno Prats M, Joseph N, Idos G, Swanson B, Kieber-Emmons A, Weiss J, Llor X. Advancing the Evaluation and Management of CDH1-Associated Gastric Cancer. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 40203872, DOI: 10.6004/jnccn.2025.7006.Peer-Reviewed Original ResearchConceptsSignet ring cell carcinomaPathogenic variant carriersGastric cancerEndoscopic surveillanceTotal gastrectomyVariant carriersGermline pathogenic variant carriersBenefits of gastrectomyCDH1 pathogenic variantsRisk of gastric cancerAdvanced gastric cancerProphylactic total gastrectomyPathogenic germline variantsFollow-up periodCumulative lifetime riskEvidence-based recommendationsUpper endoscopyCell carcinomaGlobal health concernDetected signet ring cell carcinomasGermline variantsPathogenic variantsGastrectomyGastrectomy specimensAdvanced cancer
2024
Modern Management of Gastric Neuroendocrine Neoplasms
Kunstman J, Nagar A, Gibson J, Kunz P. Modern Management of Gastric Neuroendocrine Neoplasms. Current Treatment Options In Oncology 2024, 25: 1137-1152. PMID: 39083164, DOI: 10.1007/s11864-024-01207-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsG-NENsGastrin-secreting tumorsSurgical resectionHeterogeneous group of tumorsProton pump inhibitor usageResection of visible lesionsG-NEN patientsGroup of tumorsRisk of progressionHigh-risk lesionsMetastatic diseaseNeuroendocrine tumorsNeuroendocrine neoplasmsMetastatic spreadEndoscopic resectionEndoscopic surveillanceTreatment paradigmInhibitor usageNeuroendocrine diseaseResectionTumorLow riskVisible lesionsHeterogeneous groupDe-Escalation
2023
Improving Adherence to Clinical Practice Guidelines for Managing Gastric Intestinal Metaplasia Among Gastroenterologists at a US Academic Institution
Jacob J, Millien V, Berger S, Hernaez R, Ketwaroo G, Flores A, Hou J, Jarbrink-Sehgal M, Khalaf N, Rosen D, El-Serag H, Tan M. Improving Adherence to Clinical Practice Guidelines for Managing Gastric Intestinal Metaplasia Among Gastroenterologists at a US Academic Institution. Journal Of Clinical Gastroenterology 2023, 58: 432-439. PMID: 37436841, PMCID: PMC10787041, DOI: 10.1097/mcg.0000000000001890.Peer-Reviewed Original ResearchH. pylori testingSurveillance endoscopyPreintervention cohortPostintervention studyBiopsy locationHigh-risk patientsClinical practice guidelinesGastric intestinal metaplasiaHelicobacter pylori testingPreintervention studyEndoscopic surveillanceIntestinal metaplasiaMapping biopsySurveillance recommendationsGastric mappingGIM patientsPostintervention cohortUS academic institutionsPractice guidelinesPatientsVA hospitalsClinical practiceUS hospitalsGastroenterologistsCohort
2021
Effects of Somatic Methylation in Colonic Polyps on Risk of Developing Metachronous Advanced Colorectal Lesions
Murcia O, Martínez-Roca A, Juárez M, Giner-Calabuig M, Alustiza M, Mira C, Mangas-Sanjuan C, Serrano E, Ruiz-Gómez FA, Baile-Maxia S, Medina L, Alenda C, Payá A, Rodriguez-Soler M, Zapater P, Jover R. Effects of Somatic Methylation in Colonic Polyps on Risk of Developing Metachronous Advanced Colorectal Lesions. Cancers 2021, 13: 246. PMID: 33440809, PMCID: PMC7827613, DOI: 10.3390/cancers13020246.Peer-Reviewed Original ResearchCpG island methylator phenotypeAdvanced colorectal lesionsColorectal lesionsColonic polypsRetrospective cohort studyHigh-grade dysplasiaNegative predictive valueBaseline colonoscopyCohort studyConsecutive patientsEndoscopic surveillancePathological characteristicsVillous componentSerrated lesionsPredictive valuePatientsUseful markerSomatic hypermethylationPolyp sizePolypsLesionsMethylator phenotypeSomatic methylationDysplasiaRisk
2014
Is local resection adequate for T1 stage ampullary cancer?
Amini A, Miura J, Jayakrishnan T, Johnston F, Tsai S, Christians K, Gamblin T, Turaga K. Is local resection adequate for T1 stage ampullary cancer? Hepato Pancreato Biliary 2014, 17: 66-71. PMID: 25395092, PMCID: PMC4266442, DOI: 10.1111/hpb.12297.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overAmpulla of VaterCommon Bile Duct NeoplasmsEndoscopy, Digestive SystemFemaleHumansKaplan-Meier EstimateLymph Node ExcisionLymphatic MetastasisMaleMiddle AgedNeoplasm StagingPancreaticoduodenectomyPredictive Value of TestsProportional Hazards ModelsRetrospective StudiesRisk FactorsSEER ProgramSurvival RateTime FactorsTreatment OutcomeUnited StatesWatchful WaitingConceptsAmpullary cancerRegional lymphadenectomyT1 diseaseLocal resectionFive-year survival rateAssociated with node positivityHigher-grade lesionsData of patientsLong-term survivalCases of ACNodal diseaseMetastatic diseaseNodal clearanceNodal metastasisHistological typeEndoscopic resectionEndoscopic surveillancePancreaticoduodenectomyLymphadenectomyAmpullectomySurvival rateHigh riskPatientsMultivariate modelResection
2010
Barrett's Surveillance Identifies Patients with Early Esophageal Adenocarcinoma
Wong T, Tian J, Nagar AB. Barrett's Surveillance Identifies Patients with Early Esophageal Adenocarcinoma. The American Journal Of Medicine 2010, 123: 462-467. PMID: 20399324, DOI: 10.1016/j.amjmed.2009.10.013.Peer-Reviewed Original ResearchConceptsGastroesophageal reflux diseaseEsophageal adenocarcinomaBarrett's esophagusSurveillance programReflux diseaseBarrett's surveillanceBarrett's surveillance programEarly esophageal adenocarcinomaHigh-grade dysplasiaDevelopment of dysplasiaRetrospective study designProgression of metaplasiaRisk of cancerUpper endoscopic proceduresInstitutional review boardBarrett's cohortSurveillance endoscopyMore patientsRetrospective reviewEndoscopic surveillanceBarrett's segmentSurveillance groupSurveillance periodEndoscopic proceduresNew diagnosis
2001
Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study
Montgomery E, Goldblum J, Greenson J, Haber M, Lamps L, Lauwers G, Lazenby A, Lewin D, Robert M, Washington K, Zahurak M, Hart J. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study. Human Pathology 2001, 32: 379-388. PMID: 11331954, DOI: 10.1053/hupa.2001.23511.Peer-Reviewed Original ResearchConceptsHigh-grade dysplasiaLow-grade dysplasiaBarrett's esophagusInvasive carcinomaMajority diagnosisCases of HGDCases of LGDCases of BEEndoscopic biopsy specimensKaplan-Meier statisticsInitial biopsyEndoscopic surveillanceUlcerated areaGastrointestinal pathologyBiopsy specimenPredictive markerBiopsy diagnosisBiopsy specimensIntramucosal carcinomaPrecursor lesionsIND casesPowerful prognosticatorCarcinomaMorphologic evaluationUlcerated cases
1999
Management of Barrett's esophagus: a national study of practice patterns and their cost implications
Gross C, Canto M, Hixson J, Powe N. Management of Barrett's esophagus: a national study of practice patterns and their cost implications. The American Journal Of Gastroenterology 1999, 94: ajg1999806. PMID: 10606300, DOI: 10.1111/j.1572-0241.1999.01606.x.Peer-Reviewed Original ResearchConceptsHigh-grade dysplasiaDirect medical costsBarrett's esophagusEndoscopic surveillancePractice patternsMedical costsAge 45 yrNational cross-sectional surveyCurrent practice patternsLow-grade dysplasiaMajority of cliniciansFrequency of endoscopyDegree of dysplasiaPopulation-based estimatesCross-sectional surveySurveillance endoscopyNonclinical factorsBE patientsPhysician ageCost implicationsFrequent surveillanceDysplasiaGastroenterologistsClinical decisionOptimal management
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply